ABSTRACT
224 infertile men were treated with mesterolone (M.;30, or 60 mg/die) for a minimum of three months. When comparing semen analyses done before and after treatment with M., a small but distinct reduction of hyperspermia as well as an augmentation of hypospermia were evident, an increase of sperm density in oligozoospermia grade I (20-40 kx 10(6) sperm/ml) was revealed, and an improvement of sperm motility in asthenozoospermia was seen. These was no change in sperm morphology. According to our data, careful selection of patients for treatment with M. Based on aetio-pathogenic considerations appears to be the "salient point" in the administration M. As a general rule, treatment with M. should be confined to patients with mild idiopathic oligo (astheno) zoospermia where no specific therapy - such as, e.g., high ligation for varicocele - is available.
Subject(s)
Dihydrotestosterone/analogs & derivatives , Mesterolone/therapeutic use , Semen/drug effects , Humans , Infertility, Male/drug therapy , Male , Sperm CountABSTRACT
PIP: A study of norethandrolone as a male oral contraceptive is presented. 4 subjects received 20 mg/day of the drug for 3 months concurrent with 2 or 3 subdermal capsule implants containing 20-mg testosterone. A considerable variation in sperm counts was observed during the cycle, though an azoospermic condition was not realized. Sperm counts in all subjects were markedly lower at some time during the treatment. Circulating levels of serum androgens, follicle-stimulating hormone, dihydrotestosterone, and testosterone were more consistently suppressed than were luteinizing hormone levels. Libido was slightly decreased in all subjects during treatment. All hormone levels returned to pretreatment values within 3 months of discontinued treatment. The amount of testosterone released from the capsules was between 32.2-36.4 mcg/cm/day. It is concluded that the dosage administered was inadequate for contraceptive purposes.^ieng
Subject(s)
Contraceptive Agents, Male/pharmacology , Norethandrolone/pharmacology , Spermatozoa/drug effects , Testosterone/pharmacology , Adult , Cell Count , Cell Movement , Delayed-Action Preparations , Dihydrotestosterone/blood , Follicle Stimulating Hormone/blood , Humans , Libido/drug effects , Luteinizing Hormone/blood , Male , Testosterone/administration & dosage , Testosterone/bloodABSTRACT
Whole human semen was centrifuged at various centrifugal forces to obtain sperm-free seminal plasma. Most samples of seminal plasma collected after centrifguation of up to 10,000 g were contaminated with spermatozoa. Centrifugation at 40,000 g yielded sperm-free seminal plasma in two thirds of the samples centrifuged. Filtration of whole semen with Millipore filters (pore size 0.45 mu) removed all spermatozoa.
